P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.58
    +0.04 (+1.57%)

    Market Cap: $204.65M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +48.59%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS RevisionsNo revisions (7d)
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.03+40.0%
    60d ago$-0.01+80.0%
    30d ago$-0.01+80.0%
    7d ago$-0.01+80.0%
    Current$-0.05
    Revenue Consensus
    $13M
    Range$12M - $15M
    2 analysts
    Dec 31, 2026
    EPS Consensus$0.26
    Range$0.26 - $0.26
    1 analysts
    Revenue Consensus
    $42M
    Range$40M - $44M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.26---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$0.05$-0.01+600.00%Beat+225.0%
    Mar 26
    		$0.22$-0.01+2300.00%Beat+540.0%
    Dec 25
    		$-0.07$0.04-300.00%Miss-177.8%
    Sep 25
    		$0.03$0.06-50.00%Miss+0.0%
    Jun 25
    		$-0.04$0.03-233.33%Miss-33.3%
    Mar 25
    		$-0.05$0.08-162.50%Miss+16.7%
    Dec 24
    		$0.09$0.07+28.57%Beat+228.6%
    Sep 24
    		$0.03$0.06-50.00%Miss+200.0%
    Jun 24
    		$-0.03$0.02-250.00%Miss-114.3%
    Mar 24
    		$-0.06$-0.02-200.00%Miss-20.0%
    Dec 23
    		$-0.07$-0.03-133.33%Miss+0.0%
    Sep 23
    		$-0.03N/A+57.14%Beat+57.1%
    Jun 23
    		$0.21$-0.04+625.00%Beat+290.9%
    Mar 23
    		$-0.05$-0.05+0.00%Beat+0.0%
    Dec 22
    		$-0.07N/A+53.33%Beat+53.3%
    Sep 22
    		$-0.07N/A+53.33%Beat+22.2%
    Jun 22
    		$-0.11$-0.18+38.89%Beat+56.0%
    Mar 22
    		$-0.05$-0.04-25.00%Miss+64.3%
    Dec 21
    		$-0.15$-0.11-36.36%Miss-1600.0%
    Sep 21
    		$-0.09$-0.12+25.00%Beat+35.7%
    Jun 21
    		$-0.25$-0.10-150.00%Miss-92.3%
    Mar 21
    		$-0.14$-0.17+17.65%Beat-240.0%
    Dec 20
    		$0.01N/A+112.50%Beat+0.0%
    Sep 20
    		$-0.14$-0.08-75.00%Miss+30.0%
    Jun 20
    		$-0.13$-0.20+35.00%Beat+74.0%
    Mar 20
    		$0.10N/A+133.33%Beat+120.0%
    Dec 19
    		$0.01N/A+101.59%Beat+102.7%
    Sep 19
    		$-0.20$-0.35+42.86%Beat+80.0%
    Jun 19
    		$-0.50$-0.30-66.67%Miss+37.5%
    Mar 19
    		$-0.50$-0.25-100.00%Miss+16.7%
    Dec 18
    		$-0.37$-0.45+17.78%Beat+38.3%
    Sep 18
    		$-1.00$-0.40-150.00%Miss-11.1%
    Jun 18
    		$-0.80$-0.40-100.00%Miss+25.9%
    Mar 18
    		$-0.60$-0.90+33.33%Beat-20.0%
    Dec 17
    		$-0.60$-0.60+0.00%Beat+52.8%
    Sep 17
    		$-0.90$-0.45-100.00%Miss-28.6%
    Jun 17
    		$-1.08$-0.35-208.57%Miss-
    Mar 17
    		$-0.50$-0.90+44.44%Beat-
    Dec 16
    		$-1.27$-1.10-15.45%Miss-
    Sep 16
    		$-0.70$-1.00+30.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio11.22EV/EBITDA6.81x
    Price/FCF26.91xFCF Yield3.72%
    Profitability
    Profit Margin23.50%Operating Margin23.50%
    ROE31.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage4.52x
    Current Ratio2.94xQuick Ratio1.91x
    Trading Statistics
    Beta0.01Avg Volume808.14K
    52-Week High$3.1952-Week Low$1.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.45
    SMA 20$2.43
    SMA 50$2.37
    SMA 200$2.23
    EMA 10$2.48
    EMA 20$2.43
    EMA 50$2.36
    EMA 200$2.24

    MACD

    Line: 0.05Signal: 0.03Hist: 0.02

    ADX

    ADX: 28.5+DI: 29.1-DI: 10.7

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down56.0
    PSAR$2.19

    Bollinger Bands

    Upper Band$2.64
    Lower Band$2.22
    %B Position1699%(Upper)
    Band Width0.87

    RSI (14-Day)

    Neutral
    60.8

    Momentum Oscillators

    Stoch %K76.0
    Stoch %D69.0
    Williams %R-23.4
    ROC (10d)12.7%
    Momentum0.29
    CCI (20d)133.6
    MFI (14d)72.2

    Volatility Measures

    ATR (14d)$0.11(4.3%)
    StdDev (20d)0.10
    Hist Vol60.2%(High)

    Volume Flow

    VWAP$2.57
    OBV21.6M
    AD Line819.8K
    CMF (20d)0.131

    Volume Metrics

    Avg Vol (20d)797.2K
    Vol Ratio0.9x
    VWMA (20d)$2.44

    Pivot Points

    R3$2.69
    R2$2.65
    R1$2.60
    Pivot Point$2.56
    S1$2.51
    S2$2.47
    S3$2.42

    Advanced Oscillators

    TSI12.19
    Ultimate Osc59.1
    KST34.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$19.90M$33.75M$9.12M$17.85M$15.66M$10.11M$18.22M$17.96M$13.47M$3.75M$10.49M$10.35M
    Cost of Revenue$7.76M$4.13M$4.62M$8.32M$5.87M$8.18M$3.89M$8.38M$9.46M$2.60M$8.86M$4.89M
    Gross Profit$12.13M$29.62M$4.50M$9.53M$9.79M$1.93M$14.33M$9.58M$4.02M$1.15M$1.63M$5.45M
    Operating Expenses$7.46M$8.48M$9.16M$7.40M$8.62M$6.08M$7.12M$5.59M$6.45M$6.00M$7.25M$7.34M
    R&D$4.35M$5.43M$5.63M$4.47M$5.99M$3.48M$4.12M$3.00M$2.96M$2.89M$3.10M$3.67M
    SG&A$3.11M$3.05M$3.53M$2.93M$2.62M$2.60M$3.00M$2.60M$3.48M$3.12M$4.14M$3.67M
    Operating Income$4.67M$21.15M$-4,658,000$2.13M$1.17M$-4,145,000$7.21M$3.99M$-2,427,000$-4,856,000$-5,615,000$-1,887,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$5,000$118,000$0$511,000$0$0$148,000$0$0$811,000$0
    Income Before Tax$4.86M$21.14M$-4,776,000$2.24M$661,000$-3,732,000$7.32M$3.84M$-2,272,000$-4,733,000$-6,426,000$-1,719,000
    Income Tax Expense$1.08M$2.82M$728,000$-116,000$497,000$-113,000$822,000$607,000$-69,000$-138,000$-382,000$133,000
    Net Income$3.78M$18.32M$-5,504,000$2.35M$164,000$-3,619,000$6.49M$3.24M$-2,203,000$-4,595,000$-6,044,000$-1,852,000
    EBITDA$5.27M$21.55M$-4,389,000$2.61M$1.02M$-3,386,000$7.65M$4.17M$-1,953,000$-4,411,000$-6,054,000$-1,354,000
    EBIT$4.86M$21.14M$-4,776,000$2.24M$661,000$-3,732,000$7.32M$3.84M$-2,272,000$-4,733,000$-6,426,000$-1,719,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PLX

    News

    Protalix (PLX) Q2 2026 Earnings Call Transcript

    Protalix BioTherapeutics reported strong financial results for Q2 2026, driven by Elfabrio sales and a significant milestone payment. The company reiterated its full-year 2026 revenue guidance and maintained a debt-free balance sheet with $40.7 million in cash. Protalix is advancing its PRX-115 Phase 2 RELEASE study for uncontrolled gout, with top-line results expected in late 2027, and secured a multiyear patent extension for Elfabrio in the U.S.

    The Globe and Mail•8/19/26•
    Bullish

    Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...

    Protalix BioTherapeutics Inc. reported a significant surge in net income for Q2 2026, reaching $3.8 million compared to $164,000 in Q2 2025, driven by increased Elfabrio sales. Total revenues also grew to $19.9 million. The company maintains a strong cash position and is advancing its PRS-115 gout treatment, with top-line results expected in late 2027.

    Yahoo! Finance Canada•8/12/26•
    Bullish

    Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com

    This article reports that Protalix Biotherapeutics Inc. filed a Form 8K on August 12. The filing is a routine disclosure of significant events by publicly traded companies. The article provides the date of the filing and mentions the company's stock symbol, PLX, which was down 9.92%.

    Investing.com Nigeria•8/12/26•
    Somewhat-Bearish

    Earnings call transcript: Protalix posts stronger Q2 2026 revenue, shares slip premarket

    Protalix BioTherapeutics reported a 26.8% increase in Q2 2026 revenue to $19.9 million and a net income of $3.8 million, driven by strong Elfabrio sales. Despite the positive financial results, shares dipped slightly in premarket trading due to reliance on partner orders and a pipeline that needs more time to mature. The company reaffirmed its full-year 2026 revenue guidance and is advancing its lead clinical program, PRX-115, with top-line data expected in H2 2027.

    Investing.com•8/12/26•
    Neutral

    Protalix BioTherapeutics reports Q2 revenue growth, profitability, and advances clinical trials for rare diseases.

    Protalix BioTherapeutics announced strong Q2 2026 results, with revenues of $19.8 million driven by Elfabrio® sales and total first-half revenue reaching $53.6 million, including a $25 million milestone payment. The company achieved a net income of $22.1 million year-to-date and reaffirmed its 2026 revenue guidance. Protalix is also advancing clinical trials for rare diseases, including its PRX-115 Phase 2 trial for uncontrolled gout, and maintains a solid cash position for ongoing operations.

    Pluang•8/12/26•
    Bullish

    Frequently Asked Questions About PLX

    Does PLX pay dividends?
    Protalix Biotherapeutics Inc (PLX) does not currently pay a regular dividend.
    What is PLX's P/E ratio?
    Protalix Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 11.22.
    What is PLX's market cap?
    Protalix Biotherapeutics Inc (PLX) has a market capitalization of $204.65M with a current stock price of $2.58.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In